BioMed Research International / 2009 / Article / Fig 4

Research Article

OXavidin for Tissue Targeting Biotinylated Therapeutics

Figure 4

Immunohistochemistry of avidin (a,c) or OXavidin (b,d) injected normal muscle (a,b) or MDA-MB-468 human breast carcinoma xenotransplanted mass (c,d) 48 hours after injection.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.